Skip to content

A Clinical Evaluation of Shankhprakshalan for Improving Blood Lipid Profile

Clinical study to explore the therapeutic effect of Shankhprakshalan on Dyslipidemia - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111684
Enrollment
30
Registered
2026-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

None listed

Sponsors

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients between the age group of 20-60 years of either gender Patients will be selected random of gender and socio-economic status Patients willing to participate Patients will able to perform asana Diagnosed and confirmed cases of Dyslipidaemia fulfilling at least one of the following criteria Serum Cholesterol more than 200mg/dl Serum Triglycerides more than 150mg/dl Serum LDL more than 100mg/dl Serum VLDL more than 30mg/dl Serum HDL less than 40mg/dl

Exclusion criteria

Exclusion criteria: Patients suffering from type 1 diabetes mellitus uncontrolled diabetes mellitus hypertension and mental disease. Inherited Dyslipidaemia Patient having systemic illness like tuberculosis carcinoma or major illness like renal or liver disorder Patient with CAD and cardiac disease Patient having clinical features of congestive cardiac failure Patient having any anorectal disease Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
lower lipids levelsTimepoint: within 1 week

Secondary

MeasureTime frame
NILTimepoint:

Countries

India

Contacts

Public ContactDr Dheeraj Kumar Tyagi

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan,Haridwar

dheerajtyagi@gmail.com7895617107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026